CB2 Insights (CSE:CBII,OTCQB:CBIIF) is an established, data-focused cannabis solution provider with a proven revenue model and a growing international presence. The company’s mission is to mainstream medical cannabis into traditional healthcare by providing the industry with real-world evidence-driven data through its clinical operations and contract research organization (CRO) services. Currently, the company primarily generates its revenue through its network of clinics. In the future, management intends to generate revenue from clinical trial design and management, helping other stakeholders grow their patient registry and the licensing of proprietary analytical tools that harness data taken from its clinics’ operations.
CB2 Insights CEO, Prad Sekar, and his co-founder and COO, Kash Qureshi, are entrepreneurs that have launched and managed businesses in the fields of practice management, technology, education, recruitment and medical devices. Their combined backgrounds in healthcare and technology help the company create innovative technology solutions and services that bridge the gap between patients, physicians and vendors in the cannabis industry.
CB2 Insights is focused on its multi-state US clinical network, including its brands Canna Care Docs, Relaxed Clarity and MedEval. MedEval is a service-based offering that operates a growing network of cannabis evaluation and education centers, which the company is now beginning to leverage to support clinical research efforts of major industry stakeholders. This was most recently illustrated when CB2 Insights was selected by UK-based Drug Science as the exclusive research technology platform to manage the largest medical cannabis pilot program in the UK with 20,000 patients.
Today, CB2 Insights has 34 clinics across 13 US states. In 2018, the company earned approximately $11 million in revenue and its most recent quarter signaled that its newest acquisition in New Jersey has the company on track to approach a $4 million quarter.
CB2 Insights’ Company Highlights
- Global cannabis market expected to reach US$146.4 billion by 2025.
- US CBD market projected to reach $22 billion by 2022.
- CB2 Insights operates 34 clinics across 13 US states.
- Canna Care Docs has a patient retention rate of up to 80 percent.